These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 6188914)

  • 1. Differential pharmacological properties of beta-adrenoceptor blocking drugs.
    van Zwieten PA; Timmermans PB
    J Cardiovasc Pharmacol; 1983; 5 Suppl 1():S1-7. PubMed ID: 6188914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative properties of various beta-blockers, with an outlook to the future.
    van Zwieten PA
    Clin Physiol Biochem; 1990; 8 Suppl 2():18-27. PubMed ID: 1982758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-adrenoceptor-blocking agents: are pharmacologic differences relevant?
    Clark BJ
    Am Heart J; 1982 Aug; 104(2 Pt 2):334-46. PubMed ID: 6125093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The properties of beta-adrenoceptor antagonists.
    Shanks RG
    Postgrad Med J; 1976; 52 Suppl 4():14-20. PubMed ID: 9628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-adrenergic blockade in clinical practice.
    Frishman WH
    Hosp Pract (Off Ed); 1982 Sep; 17(9):57-68. PubMed ID: 6125468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic sympathomimetic activity of beta-adrenoceptor antagonists: down-regulation of cardiac beta 1- and beta 2-adrenoceptors.
    Reithmann C; Wieland F; Jakobs KH; Werdan K
    Eur J Pharmacol; 1989 Nov; 170(3):243-55. PubMed ID: 2575997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vanidipinedilol: a vanilloid-based beta-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities.
    Yeh JL; Liou SF; Liang JC; Huang YC; Chiang LC; Wu JR; Lin YT; Chen IJ
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):51-63. PubMed ID: 10630733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-adrenoceptor blockade and intrinsic sympathomimetic activity--relevance in the treatment of ischaemic heart disease.
    Northcote RJ; Ballantyne D
    Scott Med J; 1985 Oct; 30(4):208-15. PubMed ID: 2869581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Beta-adrenergic blockers].
    Belovezhdov N
    Vutr Boles; 1986; 25(4):14-22. PubMed ID: 2876553
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.
    Joseph SS; Lynham JA; Molenaar P; Grace AA; Colledge WH; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):496-503. PubMed ID: 14608456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.
    Prichard BN
    Br J Clin Pharmacol; 1978 May; 5(5):379-99. PubMed ID: 26370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basis for cardiovascular therapy with beta-blocking agents.
    Opie LH
    Am J Cardiol; 1983 Nov; 52(9):2D-9D. PubMed ID: 6139010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The beta 2-pseudoselectivity of ISA (intrinsic sympathomimetic action)--consequences for differential therapy with beta-blockers with and without ISA?].
    Werdan K; Reithmann C
    Dtsch Med Wochenschr; 1988 Feb; 113(7):272-4. PubMed ID: 2893724
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of cardioselectivity and intrinsic sympathomimetic activity in beta-blocking drugs in cardiovascular disease.
    Taylor SH
    Am J Cardiol; 1987 May; 59(13):18F-20F. PubMed ID: 2883872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central hemodynamics of beta-adrenoceptor blocking drugs: beta 1 selectivity versus intrinsic sympathomimetic activity.
    Svendsen TL
    J Cardiovasc Pharmacol; 1983; 5 Suppl 1():S21-5. PubMed ID: 6188916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-adrenoceptor subtypes and the opening of plasmalemmal K(+)-channels in trachealis muscle: electrophysiological and mechanical studies in guinea-pig tissue.
    Cook SJ; Small RC; Berry JL; Chiu P; Downing SJ; Foster RW
    Br J Pharmacol; 1993 Aug; 109(4):1140-8. PubMed ID: 8104643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological properties of diacetolol (M & B 16,942), a major metabolite of acebutolol.
    Basil B; Jordan R
    Eur J Pharmacol; 1982 May; 80(1):47-56. PubMed ID: 6124437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic sympathomimetic activity: clinical fact or fiction?
    Taylor SH
    Am J Cardiol; 1983 Nov; 52(9):16D-26D. PubMed ID: 6139009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-adrenoceptor blocking drugs: the relevance of intrinsic sympathomimetic activity.
    Louis WJ; McNeil JJ
    Br J Clin Pharmacol; 1982; 13(Suppl 2):317S-320S. PubMed ID: 6125183
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.